Streetbeat News

Price Targets

OXY

Raymond James analyst John Freeman has maintained a Strong Buy rating on Occidental Petroleum (NYSE:OXY) but reduced the price target from $84 to $70.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 7:13 pm

LHX

Raymond James analyst Brian Gesuale has reaffirmed an Outperform rating on L3Harris Technologies (NYSE:LHX) and increased the price target from $210 to $220.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 7:10 pm

CORT

Corcept Therapeutics' stock (CORT) is trading higher following an update from Canaccord Genuity, which maintained a Buy rating on the stock and increased the price target from $37 to $38.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 7:01 pm

T

AT&T (NYSE:T) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, 2 indifferent, and no bearish ratings. Over the past three months, 5 analysts have set a 12-month price target for AT&T, averaging $18.5, with a high of $20.00 and a low of $17.00. The average price target has increased by 2.78% over the past month. Analyst ratings are based on information from company calls, financial statements, and insider conversations, and provide guidance though they are subjective opinions.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 7:01 pm

GH

Guardant Health (NASDAQ:GH) has received 7 analyst ratings in the last quarter, with 3 bullish and 4 somewhat bullish, and no indifferent, somewhat bearish, or bearish ratings. The average 12-month price target for GH is $41.57, with a high of $50.00 and a low of $27.00. This average has decreased by 20.44% from the previous average price target of $52.25. Analysts rate stocks based on research and provide guidance to investors, though their ratings are opinions and subject to human error.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 7:00 pm

JCI

Johnson Controls Intl (NYSE:JCI) has received 10 analyst ratings in the last quarter, with an average price target of $63.3, representing an upside from the current price of $51.75. The ratings include 2 bullish, 3 somewhat bullish, and 5 indifferent, with no bearish ratings. The current average price target has decreased by 5.69% from the previous target of $67.12.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 7:00 pm

EXEL

Over the last quarter, Exelixis (NASDAQ:EXEL) received 6 analyst ratings: 3 bullish, 2 somewhat bullish, and 1 indifferent. No bearish ratings were given. The 12-month price target for Exelixis averages $27.33, with a high of $30.00 and a low of $23.00. This target has increased by 11.55% in the past month. Analysts' ratings are based on financial predictions and company performance assessments.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 7:00 pm

PI

Impinj (NASDAQ:PI) has received positive ratings from analysts with 3 bullish and 1 somewhat bullish ratings in the last quarter. The average 12-month price target for Impinj is $92.25, with a high of $100.00 and a low of $85.00. This target has decreased by 10.44% from the previous target of $103.00. Analysts' ratings are based on financial predictions and are updated quarterly or after major company events.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 7:00 pm

ALGT

Over the past 3 months, 7 Wall Street analysts have published their opinions on Allegiant Travel (NASDAQ:ALGT), with 1 bullish, 2 somewhat bullish, and 4 indifferent ratings. The current average price target is $96.86, which is a 14.5% decrease from the previous target of $113.29, but still implies an upside from the current price of $73.096. Analysts' ratings are updated quarterly and are based on financial statements, meetings, and insider information.

Portfolio Pulse from Benzinga Insights

December 13, 2023 | 7:00 pm

HQY

Raymond James analyst C. Gregory Peters has reaffirmed an Outperform rating on HealthEquity (NASDAQ:HQY) and increased the price target from $90 to $95.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 6:49 pm